Continuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centre
Abstract
A clinical pathway was created to feed information into a clinical audit checklist, and was adopted as the patient-management model for biological therapies. From this, the data was reviewed concerning 41 patients who were receiving SEC between January 2014 and December 2018. The results for the Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) score which are typically reviewed at baseline and at 16 weeks to assess response to treatment.Citation
Abadie, M. et al. Continuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centre, International Journal of Current Medical And Pharmaceutical Research, Vol. 5, Issue, 04(A), pp. 4114-4118, April, 2019Journal
International Journal Of Current Medical And Pharmaceutical ResearchType
Journal articleLanguage
enae974a485f413a2113503eed53cd6c53
10.24327/23956429.ijcmpr201904635
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/